Industrial Research Laboratory, Department of Pharmacy, Birla Institute of Technology and Science (BITS), Pilani, Pilani Campus, Rajasthan 333031, India.
Birla Institute of Technology and Science (BITS), Pilani, Dubai Campus, UAE.
Ther Deliv. 2020 Apr;11(4):269-284. doi: 10.4155/tde-2020-0029.
Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease that is characterized by synovial inflammation, cellular infiltration in joints which leads to progressive joint destruction and bone erosion. RA is associated with many comorbidities including pulmonary disease, rheumatoid nodules and can have a pessimistic impact on quality of life. The current therapies of RA treatment comprise conventional, small molecule and biological antirheumatic drugs. Their utility as therapeutic agents is limited because of poor absorption, rapid metabolism and adverse effects (dose-escalation, systemic toxicity, lack of selectivity and safety). To overcome these limitations, the novel drug delivery systems are being investigated. This review has compiled currently approved therapies along with emerging advanced drug-delivery systems for RA treatment. Further, active targeting of therapeutic agents to inflamed joints via folate receptor, CD44, angiogenesis, integrins and other provided an improved therapeutic efficacy in the treatment of RA.
类风湿性关节炎（RA）是一种慢性系统性自身免疫性疾病，其特征为滑膜炎症，细胞浸润关节导致进行性关节破坏和骨侵蚀。RA 与许多合并症有关，包括肺部疾病、类风湿结节，并对生活质量产生悲观影响。目前 RA 的治疗方法包括常规、小分子和生物抗风湿药物。由于吸收不良、代谢迅速和不良反应（剂量递增、全身毒性、缺乏选择性和安全性），它们作为治疗剂的效用受到限制。为了克服这些限制，正在研究新的药物递送系统。本综述汇集了目前批准的治疗方法以及新兴的用于 RA 治疗的先进药物递送系统。此外，通过叶酸受体、CD44、血管生成、整合素和其他途径将治疗剂主动靶向到炎症关节，提高了 RA 治疗的疗效。
